LLY•benzinga•
Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential
Summary
Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by 2030.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 17, 2025 by benzinga